拓扑异构酶抑制剂放射增敏作用研究进展  

Research advances in tumor radiosensitization mediated by topoisomerase inhibitors

作　　者：汤寅[1] 张火俊[1] Tang Yin;Zhang Huojun(Department of Radiation Oncology, Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, Chin)

机构地区：[1]第二军医大学附属长海医院放射治疗科,上海200433

出　　处：《中华放射医学与防护杂志》2018年第6期466-470,共5页Chinese Journal of Radiological Medicine and Protection

基　　金：中国健康促进基金会项目（THC2015001）

摘　　要：拓扑异构酶抑制剂作为抗肿瘤化疗药物应用于临床，其放射增敏作用逐渐被人们所认识，成为放疗增敏剂中的重要一类。目前更多的拓扑异构酶抑制剂衍生物正处于基础研究及临床试验阶段，多项研究显示可能成为潜在理想的放射增敏剂，但其临床应用的理化性质、毒性作用及增敏效果仍需进一步深入研究。As anticancer drugs, topoisomerase inhibitors have been widely used in clinical practice, and their radiosensitivity has been gradually recognized. Many topoisomerase inhibitors are currently in pre-clinical and clinical studies. Several studies have shown that some topoisomerase inhibitors may be potential ideal radiosensitizers. However, the physico-chemical properties, toxicity and sensitization effects should be further investigated.

关 键 词：拓扑异构酶抑制剂 放射治疗 放射增敏 

分 类 号：R730.55[医药卫生—肿瘤]